DuoNeb Controversy
DuoNeb has been a subject of recent Medicare and U.S. Food and Drug Administration (FDA) controversy. FDA has moved for regulation of generic competition to commercial product whereas Medicare has moved to limit reimbursement of commercial product. Dispute resolution will have a material economic impact on leading respiratory service providers, as well as patients.
Read more about this topic: Ipratropium Bromide/salbutamol
Famous quotes containing the word controversy:
“Ours was a highly activist administration, with a lot of controversy involved ... but I’m not sure that it would be inconsistent with my own political nature to do it differently if I had it to do all over again.”
—Jimmy Carter (James Earl Carter, Jr.)